{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T09:54:47Z","timestamp":1776333287818,"version":"3.51.2"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kyowa Kirin Co., Ltd."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jdermsci.2021.01.002","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T19:15:47Z","timestamp":1610133347000},"page":"185-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study"],"prefix":"10.1016","volume":"101","author":[{"given":"Shinichi","family":"Imafuku","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasumasa","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Murotani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanobu","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chika","family":"Ohata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumikazu","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Miyagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidehisa","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Honma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yayoi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomotaka","family":"Mabuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Higashiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satomi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Seishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuyuki","family":"Kakuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdermsci.2021.01.002_bib0005","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0010","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","article-title":"Psoriasis prevalence among adults in the United States","volume":"70","author":"Rachakonda","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s41669-018-0104-1","article-title":"Patient and physician preferences for therapy characteristics for psoriasis: a discrete choice experiment in Japan","volume":"3","author":"Bolt","year":"2019","journal-title":"Pharmacoecon. Open"},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0020","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1477-7525-4-35","article-title":"Quality of life in patients with psoriasis","volume":"4","author":"Bhosle","year":"2006","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0025","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0030","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2005.06502.x","article-title":"Current severe psoriasis and the Rule of Tens","volume":"152","author":"Finlay","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0035","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/jdv.12576","article-title":"Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI)","volume":"29","author":"H\u00e4gg","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0040","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.3390\/ijms21051690","article-title":"Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review","volume":"21","author":"Kamata","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0045","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jdermsci.2020.06.003","article-title":"Short-term effectiveness of biologics in patients with moderate-to -severe plaque psoriasis: a systematic review and network meta-analysis","volume":"99","author":"Tada","year":"2020","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0050","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s40265-019-01136-7","article-title":"Risankizumab: first global approval","volume":"79","author":"McKeage","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0055","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","article-title":"Translating the science of quality of life into practice: what do dermatology life quality index scores mean?","volume":"125","author":"Hongbo","year":"2005","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0060","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1080\/09546634.2017.1294727","article-title":"Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab","volume":"28","author":"Elewski","year":"2017","journal-title":"J. Dermatolog. Treat."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0065","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1111\/jdv.15862","article-title":"Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials","volume":"33","author":"Blauvelt","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0070","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.jaad.2019.01.039","article-title":"Patient-reported outcomes are important elements of psoriasis treatment decision making: a discrete choice experiment survey of dermatologists in the United States","volume":"80","author":"Feldman","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0075","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s13555-019-00334-1","article-title":"Understanding treatment preferences in patients with moderate to severe plaque psoriasis in the USA: results from a cross-sectional patient survey","volume":"9","author":"Gorelick","year":"2019","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0080","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000499348","article-title":"Short-term correlation of the Psoriasis Area Severity Index, the Nail Psoriasis Area Severity Index, and the Dermatology Life Quality Index, before and after treatment, in patients with skin and nail psoriasis","volume":"5","author":"Prevezas","year":"2019","journal-title":"Skin Appendage Disord."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0085","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s13555-020-00428-1","article-title":"Association between patient- and physician-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with biologics in real life (PSO-BIO-REAL)","volume":"10","author":"Lacour","year":"2020","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0090","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jamadermatol.2016.0269","article-title":"Effect of ixekizumab treatment on work productivity for patients with moderate-to-severe plaque psoriasis: analysis of results from 3 randomized phase 3 clinical trials","volume":"152","author":"Armstrong","year":"2016","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0095","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/jdv.13032","article-title":"A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab","volume":"30","author":"Edson-Heredia","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0100","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.jaad.2016.07.034","article-title":"Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: results from 3 phase III psoriasis clinical trials","volume":"75","author":"Kimball","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0105","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1346-8138.2011.01459.x","article-title":"Dramatic impact of a psoriasis area and severity index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab","volume":"39","author":"Torii","year":"2012","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0110","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/jdv.15878","article-title":"Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort study in the French psoriasis registry PSOBIOTEQ","volume":"34","author":"Masson Regnault","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0115","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1111\/jdv.15733","article-title":"Female patients are less satisfied with biological treatment for psoriasis and experience more side-effects than male patients: results from the prospective BioCAPTURE registry","volume":"33","author":"van der Schoot","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0120","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/1346-8138.13409","article-title":"Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: results of SALSA study","volume":"43","author":"Asahina","year":"2016","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0125","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/jdv.13803","article-title":"DLQI as a major criterion for introduction of systemic agents in patients with mild psoriasis","volume":"30","author":"Mermin","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0130","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s11136-015-1224-z","article-title":"Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice","volume":"25","author":"Shear","year":"2016","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0135","doi-asserted-by":"crossref","first-page":"481","DOI":"10.4103\/2229-5178.193908","article-title":"General measures and quality of life issues in psoriasis","volume":"7","author":"Sarkar","year":"2016","journal-title":"Indian Dermatol. Online J."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0140","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/1346-8138.15196","article-title":"Biologics Review Committee of the Japanese Dermatological Association for Psoriasis: Chair: M. Ohtsuki, Japanese guidance for use of biologics for psoriasis (the 2019 version)","volume":"47","author":"Saeki","year":"2020","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0145","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/bjd.15314","article-title":"Comparison of the paper-based and electronic versions of the Dermatology Life Quality Index: evidence of equivalence","volume":"177","author":"Ali","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0150","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s11136-015-0937-3","article-title":"Equivalence of electronic and paper-based patient-reported outcome measures","volume":"24","author":"Campbell","year":"2015","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0155","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2340\/00015555-1456","article-title":"Improvement in Psoriasis Area and Severity Index score predicts improvement in skin pain over time in patients with psoriasis","volume":"93","author":"Ljosaa","year":"2013","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0160","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jad.2008.06.026","article-title":"The PHQ-8 as a measure of current depression in the general population","volume":"114","author":"Kroenke","year":"2009","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0165","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0170","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.sleep.2008.06.003","article-title":"Psychometric evaluation and tests of validity of the Medical Outcomes Study 12-item Sleep Scale (MOS sleep)","volume":"10","author":"Allen","year":"2009","journal-title":"Sleep Med."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0175","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1477-7525-7-36","article-title":"Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications","volume":"7","author":"Bharmal","year":"2009","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0180","first-page":"47","article-title":"Developing a Japanese version of the EQ-5D-5L value set","volume":"64","author":"Ikeda","year":"2015","journal-title":"J. Natl. Inst. Public Health"},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0185","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0190","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/bjd.17128","article-title":"Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management","volume":"179","author":"Augustin","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0195","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1159\/000345715","article-title":"Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice","volume":"225","author":"Norlin","year":"2012","journal-title":"Dermatology"},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0200","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0205","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14337","article-title":"Psoriatic patients undergoing long-term therapy with biologics: impact of residual localization of psoriasis on quality of life in an Italian clinical setting","author":"Muslimani","year":"2020","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0210","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/bjd.17689","article-title":"Localization of treatment-resistant areas in patients with psoriasis on biologics","volume":"181","author":"Hjuler","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0215","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/JDN.0000000000000418","article-title":"Manifestations and management of difficult-to-treat psoriasis","volume":"10","author":"Aldredge","year":"2018","journal-title":"J. Dermatol. Nurses Assoc."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0220","first-page":"84","article-title":"Psoriasis affects patient\u2019s quality of life more seriously in female than in male in Japan","volume":"37","author":"Mabuchi","year":"2012","journal-title":"Tokai J. Exp. Clin. Med."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0225","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/jdv.15324","article-title":"Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice","volume":"33","author":"Maul","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0230","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/jdv.14676","article-title":"A detailed analysis of \u2018not relevant\u2019 responses on the DLQI in psoriasis: potential biases in treatment decisions","volume":"32","author":"Rencz","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0235","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0190-9622(98)70114-8","article-title":"Omega-3 fatty acid-based lipid infusion in patients with chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, multicenter trial","volume":"38","author":"Mayser","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0240","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000333358","article-title":"Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis","volume":"224","author":"Nishioka","year":"2012","journal-title":"Dermatology"},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0245","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/jid.2011.238","article-title":"Can we rely on the Dermatology Life Quality Index as a measure of the impact of psoriasis or atopic dermatitis?","volume":"132","author":"Twiss","year":"2012","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2021.01.002_bib0250","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/bjd.16927","article-title":"Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis","volume":"179","author":"Rencz","year":"2018","journal-title":"Br. J. Dermatol."}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181121000025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181121000025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T04:50:55Z","timestamp":1760331055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181121000025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0923181121000025"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2021.01.002","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2021.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V. on behalf of Japanese Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}